Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 11/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 11/20 | 0.49 |
| ▸ | NPC1 | O15118 | 11/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.42 |
| ▸ | MAPT | P10636 | 9/20 | 0.42 |
| ▸ | TP53 | P04637 | 4/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 6/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17480635 | 0.86 | PDK1 (0.42) | PDK1RAB9ASMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL16285306 | 0.81 | PDK1 (0.38) | PDK1RAB9ASMN1; SMN2NPC1MAPT | |
| SCHEMBL10022444 | 0.81 | PDK1 (0.38) | PDK1RAB9ASMN1; SMN2NPC1MAPT | |
| SCHEMBL798495 | 0.81 | PDK1 (0.38) | PDK1RAB9ASMN1; SMN2NPC1MAPT | |
| SCHEMBL10022442 | 0.79 | DRD2 (0.43) | PDK1RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL24805722 | 0.75 | GRM5 (0.36) | PDK1 | |
| SCHEMBL8366464 | 0.75 | PDK1 (0.62) | PDK1RAB9ASMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL5207812 | 0.75 | PDK1 (0.62) | PDK1RAB9ASMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL10022441 | 0.74 | PDK1 (0.33) | PDK1ALDH1A1 | |
| SCHEMBL14754934 | 0.73 | DRD3 (0.67) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165322-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165322-A1 | RHO KINASE INHIBITORS | ROCK1, ROCK2, RHOA | PDK1 459/4885RAB9A 100/4885SMN1; SMN2 1326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.